Clinics are selling BPC-157 "before the rules change" — but the rules haven't changed at all

The vote hasn't made anything legal. Here's the history that tells you how long this really takes — plus a genuinely confusing GLP-1 bone finding.

What does "advisory" actually mean — in time?

We've said the July vote was "advisory, not final" many times. Here's what that means in calendar terms, because the number is genuinely clarifying.

The last time this committee added substances to the compounding list, the cycle ran from the advisory meetings in 2015, to a proposed rule in December 2016, to a final rule effective March 2019 — roughly four years end to end. And the FDA issued a second proposed rule in September 2019 to add five more substances; that one has never been finalized — it's been pending nearly seven years. So "advisory" doesn't mean "almost there." It means the beginning of a process measured in years, that sometimes never completes at all.

The story of the last two weeks isn't the FDA — it's the clinics not waiting for it

Telehealth and peptide companies are now advertising BPC-157 with language like "the FDA panel just recommended BPC-157 — you don't have to wait for final rulemaking," pitching prescriptions today on the strength of a vote that changed nothing legally. One publicly traded peptide company put out a celebratory release; multiple direct-to-consumer clinics are running "check availability now" funnels.

Let's be precise about why that's misleading. The advisory vote did not make BPC-157 legal to compound. As one industry law firm summarized this month, the peptides remain in a gray zone — removed from the banned list, but not added to the approved list, and not FDA-approved. Federal law works on a positive list: if a substance isn't affirmatively on the compounding list, it defaults to an unapproved new drug, and prescribing it carries the same enforcement risk it did before the vote. A recommendation is not a rule.

So when a clinic tells you "you don't have to wait," what they mean is "we've decided the enforcement risk is worth it — to us." The peptide you'd receive is the same unapproved, thinly-studied compound it was in June; the only thing the vote changed is the marketing confidence around selling it. That's the honest translation.

The credibility-transfer move, now with a regulatory costume

For months we've tracked how the hyped peptides borrow GLP-1s' hard-earned reputation. This month adds a new layer: borrowing the vote's authority. "FDA panel recommended" is being used exactly the way "it's a peptide, like Ozempic" was — as a credential the product didn't earn.

But notice what the vote actually was: a narrow recommendation. The committee evaluated BPC-157 specifically for ulcerative colitis — not tendon repair, not gut healing in general, not anti-aging, not the dozen things it's marketed for. Even in the best case where it eventually reaches the compounding list, the evidence the panel weighed was for one condition. Everything else is off-label extrapolation.

The keeper concept: a recommendation for X is being marketed as endorsement of A through Z. When you see "FDA-recommended peptide," ask recommended for what, exactly? The honest answer is almost always narrower — and thinner — than the ad implies.

A genuinely confusing GLP-1 bone finding — reported honestly, wrinkles and all

We've consistently flagged that GLP-1s drive loss of muscle and bone density, which matters especially in menopause when estrogen loss already threatens bone. That's still true, and new data this year reinforces it: larger, longer studies link semaglutide- and tirzepatide-associated weight loss to meaningful declines in spine, hip, and femoral-neck bone density, with the loss tracking the amount of weight lost.

But here's the wrinkle a careful reader deserves: a separate analysis presented at a major endocrine meeting this year found semaglutide associated with a 15% reduction in fractures compared with other weight-loss approaches. How can bone density drop and fractures fall? Plausibly because the other benefits — less weight to carry, better blood sugar, improved balance and mobility, less fall risk — can offset the density loss in real-world outcomes. The density scan and the fracture rate are measuring different things.

The honest synthesis, which is the whole point: this is genuinely unsettled, and anyone giving you a clean "GLP-1s are bad for bones" or "GLP-1s protect bones" is overselling a mixed, evolving picture. What isn't unsettled is what to do about it — and it's the same unglamorous advice regardless of how the density-vs-fracture question resolves: if you're on a GLP-1, resistance training (even twice a week) and adequate protein are the highest-leverage things you can do to protect muscle and bone. The science is still arguing; the countermeasure isn't.

That's the Peptune posture in miniature: hold the uncertainty honestly, and still give you the thing that helps no matter which way it breaks.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.

← All issues